Eight members of Congress wrote to FDA Center for Veterinary Medicine director Dr. Steven Solomon this week to express concern that CVM’s GFI 256 on animal compounding may result in delayed care for veterinary patients. read more →
Several changes to NABP’s new Model Act were recommended by APC, including a requirement that licensed compounding pharmacies provide to the state board of pharmacy basic information about their compounding operations. read more →
One hundred members of Congress signed a letter of concern sent last week to the Department of Defense in response to recent TRICARE changes that threaten beneficiaries’ access to community pharmacies, especially in rural areas. read more →
In a Sep 16 letter to NABP CEO Al Carter, FDA states that DTE products “can put patients at harm” and that “therapies containing DTE are biological products subject to licensure under Section 351(i) of the PHS Act.” read more →
One result of last week’s Compounders on Capitol Hill visits has been the creation of a joint congressional letter to FDA’s Center for Veterinary Medicine raising concerns about the great ambiguity in GFI 256 on animal compounding read more →
Marcy Bliss, chief executive officer of Wedgewood Pharmacy in Swedesboro, New Jersey, was named the 2021 George and Lucy Malmberg Compounding Advocacy Champion at APC’s Compounders on Capitol Hill. Congratulations, Marcy!